Generic placeholder image

Mini-Reviews in Medicinal Chemistry


ISSN (Print): 1389-5575
ISSN (Online): 1875-5607

Review Article

LHRH-Targeted Drug Delivery Systems for Cancer Therapy

Author(s): Xiaoning Li, Oleh Taratula, Olena Taratula, Canan Schumann and Tamara Minko

Volume 17, Issue 3, 2017

Page: [258 - 267] Pages: 10

DOI: 10.2174/1389557516666161013111155

Price: $65


Targeted delivery of therapeutic and diagnostic agents to cancer sites has significant potential to improve the therapeutic outcome of treatment while minimizing severe side effects. It is widely accepted that decoration of the drug delivery systems with targeting ligands that bind specifically to the receptors on the cancer cells is a promising strategy that may substantially enhance accumulation of anticancer agents in the tumors. Due to the transformed cellular nature, cancer cells exhibit a variety of overexpressed cell surface receptors for peptides, hormones, and essential nutrients, providing a significant number of target candidates for selective drug delivery. Among others, luteinizing hormonereleasing hormone (LHRH) receptors are overexpressed in the majority of cancers, while their expression in healthy tissues, apart from pituitary cells, is limited. The recent studies indicate that LHRH peptides can be employed to efficiently guide anticancer and imaging agents directly to cancerous cells, thereby increasing the amount of these substances in tumor tissue and preventing normal cells from unnecessary exposure. This manuscript provides an overview of the targeted drug delivery platforms that take advantage of the LHRH receptors overexpression by cancer cells.

Keywords: Cancer, drug delivery systems, GnRH, LHRH, nanoparticles, targeted delivery.

Rights & Permissions Print Export Cite as
© 2023 Bentham Science Publishers | Privacy Policy